Work

Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.e20528

Authors: Brandon R. Shank, Brian Primeaux, Sandra B. Horowitz, Erin K. Yeung, Irene Y. Lee, Gregory Peter Kaufman, Hans Chulhee Lee, Elisabet Esteve Manasanch, Krina K. Patel, Robert Z. Orlowski, Donna M. Weber, Sheeba K. Thomas

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3028821945

Cites:

Cited by:

Related to: 10